Sign In
Last checked at 
9 Apr 2018 17:39
Director Dealings / Market Share Purchase
Oxford, UK - 09 April 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Andrew Heath, Deputy Chairman and Senior Independent Director has purchased 192,914 ordinary shares of 1p each ("Ordinary Shares") in the Company on 09 April 2018 on the London Stock Exchange at a price of 10.9p per share. Following this purchase Dr. Andrew Heath holds 1,800,000 ordinary shares representing 0.06% of the Company.
120,720 Ordinary Shares were purchased by Dr. Heath's wife (Eva Lackner) and are therefore considered a beneficial holding of Dr. Heath. The balance was purchased in his own name.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
1. | Details of the person discharging material responsibilities/person closely associated
| ||
a. | Name | Dr. Andrew Heath
| |
2. | Reason for the notification
| ||
a. | Position/status | Deputy Chairman and Senior Independent Director
| |
b. | Initial notification /amendment | Initial notification
| |
3. | Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
| ||
a. | Name | Oxford BioMedica plc
| |
b. | Legal Entity Identifier | 213800S1GVQNXQ15K851
| |
4. | Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
a. | Description of the financial instrument, type of instrument identification code | Oxford BioMedica plc Ordinary Shares of 1p each
GB0006648157
| |
b. | Nature of the transaction | Purchase of ordinary shares
| |
c. | Currency | GBP - British Pound
| |
d. | Price(s) and volume(s) |
Price(s)
|
Volume(s) |
|
| £0.11 | 72,194 |
e. | Aggregated information · Aggregated volume · Price · Aggregated total
|
72,194
£0.109 £7,834.20
| |
f. | Date of the transaction | 2018-04-09
| |
g. | Place of the transaction | London Stock Exchange, Main Market (XLON)
| |
1. | Details of the person discharging material responsibilities/person closely associated
| ||
a. | Name | Eva Lackner
| |
2. | Reason for the notification
| ||
a. | Position/status | Person closely associated with Dr. Andrew Heath, Deputy Chairman and Senior Independent Director
| |
b. | Initial notification /amendment | Initial notification
| |
3. | Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
| ||
a. | Name | Oxford BioMedica plc
| |
b. | Legal Entity Identifier | 213800S1GVQNXQ15K851
| |
4. | Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
a. | Description of the financial instrument, type of instrument identification code | Oxford BioMedica plc Ordinary Shares of 1p each
GB0006648157
| |
b. | Nature of the transaction | Purchase of ordinary shares
| |
c. | Currency | GBP - British Pound
| |
d. | Price(s) and volume(s) |
Price(s)
|
Volume(s) |
£0.11 | 720 | ||
£0.11 | 120,000 | ||
e. | Aggregated information · Aggregated volume · Price · Aggregated total
|
120,720
£0.109 £13,101.48
| |
f. | Date of the transaction | 2018-04-09
| |
g. | Place of the transaction | London Stock Exchange, Main Market (XLON)
| |
The issued share capital of the Group is 3,283,790,680 ordinary 1p shares.
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer Stuart Paynter, Chief Financial Officer |
Tel: +44 (0)1865 783 000 |
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
|
Tel: +44 (0)20 3709 5700 |
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.
Follow the stocks
